• STAT+: FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

    1 month ago - By STAT

    In a long-awaited move, the Food and Drug Administration has approved the first so-called interchangeable biosimilar version of insulin, which the agency suggested may reduce the price of a life-saving treatment that has been a poster child for the high cost of medicines.
    The agency endorsed Semglee, a copy of long-acting Lantus , that it first approved last year. Now, though, the copycat version has also been designated as interchangeable, a regulatory term that means Semglee can be substituted at the pharmacy for Lantus in the same way that generic drugs are substituted for equivalent...
    Read more ...

     

  • Opinion: A double vaccine crisis is endangering millions of children

    1 month ago - By STAT

    World health experts met recently to discuss an emerging global health crisis linked to the Covid-19 pandemic: plummeting rates of basic vaccinations among the world's children.
    While many experts have been acutely aware of the pandemic's impact on essential health services, startling new immunization data from the World Health Organization and UNICEF indicate that decades of progress against some of the world's most dangerous diseases is being severely threatened.
    Read more ...

     

  • STAT+: Pharmalittle: Emergent to resume Covid-19 vaccine production; FDA OKs first interchangeable biosimilar insulin

    1 month ago - By STAT

    Everyone, and how are you today? We are just fine, thank you, despite gray skies hovering over the Pharmalot campus. Despite the looming rain, our spirits remain sunny. As the Morning Mayor taught us long ago: Every new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will fire up the coffee kettle for another needed cup of stimulation. Our choice today is glazed doughnut. Yum. Meanwhile, here are a few choice items of interest we have assembled for you. Hope your journey is smooth, and do stay in touch....
    Since the controversial approval of the Alzheimer's...
    Read more ...